“To meet the growing AI demand, over the next two years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI.”

In context

“ation for investigation in younger pediatric patients aged six to 11 in hemophilia B with or without inhibitor. That's an important innovative medicine today, and we are investigating the full potential of Hymbabsi to support more patients living with hemophilia. Our third strategic priority is investing to maximize post-2028 growth. We are committed to fully supporting a robust and accelerated approach to R&D, the successful commercial launch of new products, and bolt-on business development while maintaining our robust dividend. And finally, we are scaling artificial intelligence across R&D, manufacturing, commercial, and patient engagement to improve productivity and accelerate innovation. We have been setting the foundation with AI already, data agenda workflows, and compute capacity. To meet the growing AI demand, over the next two years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI. In R&D, we are embedding AI across discovery, development, regulatory, and medical to increase productivity and accelerate the pipeline and timelines. AI is optimizing supply planning and manufacturing, contributing to our manufacturing optimization program goals. In commercial, AI is helping to accelerate new product launches, delivering insights for dynamic targeting, and supporting personalized messaging and real-time marketing content. So with that and after I described the four priorities, which describe the full picture of what you plan to do in 2026, I will turn it over to Chris to discuss the news of the day, which are the Metaira long-acting announcement of Vespar three. Chris. Chris Boshoff: Thank you, Albert. It is my pleasure to discuss the VSPR three study results today and p”